PV Readiness Guide

Pharmacovigilance (PV) is the science and activities concerned with detecting, assessing, understanding, and preventing adverse effects or other medicine-related problems. Readiness therefore means more than possessing standard operating procedures (SOPs). A ready organisation can show that safety information moves reliably from each source to an appropriate decision, regulatory submission, and documented follow-up.

In Nigeria, the certificate of registration holder remains accountable for the local PV system, including work performed by distributors, service providers, or other partners. NAFDAC’s 2024 inspection guidance allows the Agency to examine the systems, personnel, procedures, and facilities used to meet PV obligations. Readiness must be designed into routine operations rather than assembled shortly before an inspection.

If your team needs a practical self-assessment, download the NAFDAC QPPV Compliance Checklist to compare current processes against inspection-ready expectations.

Start with accountable governance

Senior management should approve a written PV governance model that identifies the local Qualified Person Responsible for Pharmacovigilance (QPPV), a suitably qualified backup, reporting lines, delegated activities, decision rights, and escalation routes. The QPPV should have sufficient authority, continuous access to relevant safety information, and oversight of the pharmacovigilance system master file (PSMF).

The PSMF should accurately describe the system that is operating. It should be supported by current organisation charts, product and partner lists, SOPs, safety-data exchange agreements, training records, compliance metrics, audit schedules, and change-control history. A mismatch between the PSMF and actual practice is itself a readiness concern. Third-party agreements should state who receives safety information, who assesses and submits it, applicable timelines, reconciliation methods, and how urgent issues are escalated.

This governance foundation is closely related to our QPPV Support Essentials article and the broader pharmacovigilance services we provide for local and regional teams.

Control the full case-handling pathway

Every potential safety source should be mapped. Sources may include medical information, product complaints, market research, patient-support programmes, digital channels, partners, literature, studies, and spontaneous reports. Staff who are not part of the PV unit still need role-specific training so that reportable information reaches PV promptly.

Case procedures should cover intake, validation, duplicate search, seriousness and expectedness assessment, coding, follow-up, medical review, quality control, submission, acknowledgement, and archiving. The local reporting calendar must be based on the current NAFDAC rules and any applicable study or contractual requirements. For example, the 2021 NAFDAC GVP guideline specifies 15-calendar-day reporting for serious adverse reactions and certain important situations. Organisations should verify the latest requirement for each case category rather than apply one timeline to every report.

Useful performance measures include time from first receipt to PV intake, overdue submissions, follow-up completion, duplicate rate, quality-control findings, partner reconciliation discrepancies, and cases awaiting medical review. Metrics require thresholds, owners, and documented action when performance falls outside tolerance.

Make signal review a governed decision process

A safety signal is not established merely because one event has been reported. Signal management should define how information is detected, validated, prioritised, assessed, recommended for action, communicated, and closed. Review should combine individual cases with aggregate data, scientific literature, product complaints, exposure information, class effects, clinical data, and relevant regulatory actions.

ICH E2E recommends prospective PV planning based on a safety specification and identified knowledge gaps, particularly around early post-marketing use. The signal calendar should therefore be proportional to product risk and exposure. Each review should retain the search strategy, data reviewed, clinical reasoning, decision, responsible persons, due date, and evidence that agreed actions were completed.

Teams that are strengthening safety oversight may also find value in our Drug Safety in Nigeria guide and our regulatory services for connecting compliance activity to broader obligations.

Prepare evidence, not a performance

Inspection preparation should test whether the system can retrieve complete evidence quickly. Conduct a risk-based mock inspection using recent cases, a product with an emerging issue, a partner reconciliation cycle, an overdue item, and a closed corrective and preventive action (CAPA). Trace each item from receipt to final disposition.

A practical readiness cycle is to maintain an indexed inspection repository, review high-risk metrics monthly, reconcile safety data with partners at defined intervals, test QPPV and backup availability, complete periodic PSMF reviews, and verify CAPA effectiveness. NAFDAC’s inspection framework includes routine and targeted inspections, so readiness should be continuous.

The objective is not a perfect file room. It is a controlled system that protects patients, produces reliable safety information, identifies problems early, and demonstrates how the organisation learns from them. That discipline also supports better decision-making across medical information, resources, and wider compliance work.

References

1. World Health Organization. Pharmacovigilance. Accessed July 18, 2026. https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance
2. National Agency for Food and Drug Administration and Control. Pharmacovigilance inspection guidelines for Nigeria regulated drugs. Published October 15, 2024. Accessed July 18, 2026. https://nafdac.gov.ng/wp-content/uploads/Files/Resources/Guidelines/PVG_GUIDELINES/Pharmacovigilance-Inspection-Guidelines-For-Nigeria-Regulated-Drugs.pdf
3. National Agency for Food and Drug Administration and Control. Guidelines for Qualified Person for Pharmacovigilance. Published 2024. Accessed July 18, 2026. https://nafdac.gov.ng/wp-content/uploads/Files/Resources/Guidelines/PVG_GUIDELINES/Guidelines-For-Qualified-Person-For-Pharmacovigilance-1.pdf
4. National Agency for Food and Drug Administration and Control. Good pharmacovigilance practice guidelines. Effective January 21, 2021. Accessed July 18, 2026. https://www.nafdac.gov.ng/wp-content/uploads/Files/Resources/Guidelines/PVG_GUIDELINES/NAFDAC-Guidelines-on-Good-Pharmacovigilance-2021.pdf
5. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH E2E: Pharmacovigilance planning. Published November 18, 2004. Accessed July 18, 2026. https://database.ich.org/sites/default/files/E2E_Guideline.pdf